|Bid||152.81 x 800|
|Ask||0.00 x 800|
|Day's Range||149.84 - 152.39|
|52 Week Range||70.80 - 168.98|
|Beta (3Y Monthly)||0.24|
|PE Ratio (TTM)||565.99|
|Earnings Date||Nov 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||145.06|
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2019 on November 5, 2019 after the close of the financial markets. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 3163969. Insulet Corporation (PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.
The Massachusetts-based medical device company Insulet Corporation (NASDAQ: PODD ) said Monday that the FDA has approved its Alternate Controller Enabled Infusion, or ACE, pump. This allows Insulet to ...
Insulet Corporation (PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for an Alternate Controller Enabled Infusion Pump (ACE Pump). This allows Insulet to market its Omnipod DASH™ Insulin Management System (Omnipod DASH System) as an integrated insulin pump (Omnipod DASH ACE Pump), allowing it to be a part of an interoperable automated insulin delivery (AID) system, such as the Company's Omnipod Horizon™ Automated Insulin Delivery System1.
Dow Jones futures jumped Wednesday, signaling a stock market rally on Hong Kong and other news. Coupa Software stock soared to a buy zone.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results ...
Insulet Corporation (PODD) (Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), has priced a private placement of $700 million aggregate principal amount of convertible senior notes due 2026 (the Notes). Insulet also granted the initial purchasers of the Notes an option to purchase up to an additional $100 million aggregate principal amount of Notes in the private placement. The conversion rate will initially be 4.4105 shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $226.73 per share of Insulet common stock, which represents a premium of approximately 35.0% to the $167.95 per share closing price of Insulet common stock on September 3, 2019), subject to adjustment in certain circumstances.
Today we are going to look at Insulet Corporation (NASDAQ:PODD) to see whether it might be an attractive investment...
The year-over-year improvement in Insulet's (PODD) revenues owing to the solid adoption of Omnipod system, both in the United States and the international markets, encourages us.
Insulet (PODD) delivered earnings and revenue surprises of -33.33% and 8.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?